Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study

PURPOSE: The LORDSHIPS study aimed to explore the safety and efficacy of a novel fully oral triplet combination of dalpiciclib (a potent cyclin-dependent kinase 4/6 inhibitor), pyrotinib (a HER2 tyrosine kinase inhibitor) and endocrine therapy letrozole in patients with HER2-positive, hormone recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, Meng, Yanchun, Wang, Biyun, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Li, Ting, Yao, Wenqing, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936075/
https://www.ncbi.nlm.nih.gov/pubmed/35321427
http://dx.doi.org/10.3389/fonc.2022.775081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936075/
https://www.ncbi.nlm.nih.gov/pubmed/35321427
http://dx.doi.org/10.3389/fonc.2022.775081

Ejemplares similares